Isager Peter, Ehlers Niels, Urbak Steen F, Overgaard Jens
Department of Ophthalmology, Arhus University Hospital, Denmark.
Acta Oncol. 2006;45(3):285-93. doi: 10.1080/02841860500468950.
To study the visual outcome, local tumour control, and eye preservation 5 years after ruthenium/rhodium 106 brachytherapy for choroidal melanoma. The study included 55 consecutive patients treated by 106Ru/Rh brachytherapy for a choroidal melanoma during the period 1988-2000 and followed through 2004. The 5-year probability for not losing at least 5 Snellen lines was 59% (n = 45), for retaining a visual acuity of 0.33 or better was 28% (n = 34), and for retaining better than 0.1 was 40% (n = 45). The 5-year probability for no local recurrence was 73% and for eye preservation 72% (n = 55). 106Ru/Rh brachytherapy for choroidal melanoma resulted in a clinically significant vision loss, no local recurrence, and eye preservation in most patients after 5 years. 106Ru/Rh brachytherapy can be regarded as a good treatment option for small and medium-sized tumours but not for large tumours.
研究脉络膜黑色素瘤经钌/铑106近距离放射治疗5年后的视力结果、局部肿瘤控制情况和眼球保留情况。该研究纳入了1988年至2000年期间连续接受106Ru/Rh近距离放射治疗脉络膜黑色素瘤的55例患者，并随访至2004年。至少不丧失5行斯内伦视力表视力的5年概率为59%（n = 45），保持0.33或更好视力的概率为28%（n = 34），保持优于0.1视力的概率为40%（n = 45）。无局部复发的5年概率为73%，眼球保留的5年概率为72%（n = 55）。脉络膜黑色素瘤经106Ru/Rh近距离放射治疗5年后，大多数患者出现了临床上显著的视力丧失，无局部复发，且眼球得以保留。106Ru/Rh近距离放射治疗可被视为中小型肿瘤的良好治疗选择，但不适用于大型肿瘤。
